| Database ID | Agent | Target | Cancer Type | Detail |
| DB00901 | tivozanib (AV951) and everolimus (RAD001) | NA | colorectal cancer | view |
| DB00902 | sunitinib | FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor | advanced solid tumors | view |
| DB00903 | pasireotide (SOM 230) + everolimus (RAD001) | pasireotide:Somatostatin receptor type 1, 2, 3, 5 | neuroendocrine tumour | view |
| DB00904 | vandetanib | Epidermal growth factor receptor
Vascular endothelial growth factor receptor 2
Protooncogene tyrosineprotein kinase receptor ret | colorectal cancer | view |
| DB00905 | panitumumab | Epidermal growth factor receptor | colorectal cancer | view |
| DB00906 | bevacizumab | Vascular endothelial growth factor | advanced solid tumors | view |
| DB00907 | foretinib | Vascular endothelial growth factor receptor 2
Hepatocyte growth factor receptor | advanced solid tumors | view |
| DB00908 | bevacizumab | Vascular endothelial growth factor | biliary tract and gallbladder cancer | view |
| DB00909 | cetuximab | Epidermal growth factor receptor | liver cancer | view |
| DB00910 | bevacizumab and erlotinib | NA | colorectal cancer | view |
| DB00911 | gefitinib | Epidermal growth factor receptor | colorectal cancer | view |
| DB00912 | gefitinib | Epidermal growth factor receptor | colorectal cancer | view |
| DB00913 | cetuximab | Epidermal growth factor receptor | colorectal cancer | view |
| DB00914 | bevacizumab | Vascular endothelial growth factor | liver cancer | view |
| DB00915 | erlotinib | Epidermal growth factor receptor | colorectal cancer | view |